Clinical Guides
Hepatocellular Carcinoma
A clinically focused, India-adapted guide to hepatocellular-carcinoma prevention, surveillance, imaging diagnosis, liver-function and tumour staging, curative and locoregional treatment, systemic therapy, transplant referral and decompensation safety, with explicit resource and jurisdiction limits.
MedNext Academy | 13 min read
Hepatocellular Carcinoma
A clinically focused, India-adapted guide to hepatocellular-carcinoma prevention, surveillance, imaging diagnosis, liver-function and tumour staging, curative and locoregional treatment, systemic therapy, transplant referral and decompensation safety, with explicit resource and jurisdiction limits.
Summary
Hepatocellular carcinoma (HCC) is the predominant primary malignancy arising from hepatocytes and usually develops in a liver already damaged by chronic hepatitis B or C, alcohol-related disease, metabolic dysfunction-associated steatotic liver disease or another cause of cirrhosis. It is clinically unusual because prognosis and treatment depend on two interacting conditions: tumour burden and the functional reserve of the background liver. A technically possible cancer treatment may be unsafe in portal hypertension or decompensated cirrhosis, while treating the liver disease alone does not control established cancer.
People at sufficient risk need structured surveillance rather than symptom-triggered testing. A new lesion is assessed with multiphasic contrast CT or MRI using validated imaging criteria. In a defined at-risk population, characteristic arterial hyperenhancement and washout can establish HCC non-invasively; outside that population, or when imaging is indeterminate, biopsy is often required. Alpha-fetoprotein supports surveillance or prognosis in selected contexts but cannot diagnose or exclude HCC by itself.
Management is multidisciplinary and stage-adapted. Potentially curative options are resection, ablation and liver transplantation. Transarterial, radiation-based and systemic treatments serve selected intermediate or advanced disease, with choices shaped by liver function, portal hypertension, performance status, vascular invasion, extrahepatic spread and access. Acute variceal bleeding, encephalopathy, sepsis, spontaneous bacterial peritonitis, severe jaundice or rupture with haemoperitoneum is an emergency. This quarantined guide does not prescribe a regimen and has been reviewed by the MedNext Clinical Team.
How Common Is It?
HCC produces a major global mortality burden and represents most primary liver cancers, but its distribution is uneven because chronic viral hepatitis, alcohol exposure, metabolic disease, aflatoxin, vaccination, antiviral access and population age differ. Indian estimates are particularly sensitive to geography and data source. The National Viral Hepatitis Control Programme describes a substantial chronic hepatitis burden and cites hepatitis B and C as important contributors to Indian HCC; the programme also states that the exact national viral-hepatitis burden is not established. Those older programme estimates should be labelled by date and should not be converted into a current patient-specific probability.
Hospital series over-represent symptomatic and advanced disease, whereas cancer registries cover defined catchment populations and may miss undiagnosed cases. A rising number of metabolic liver disease cases may change future aetiology, but the size of that change cannot be inferred from a tertiary-clinic cohort. HCC can occur without cirrhosis, particularly in chronic hepatitis B and some metabolic disease, yet cirrhosis remains the dominant practical risk state.
Burden is better understood through preventable drivers and stage at discovery than through one headline percentage. Hepatitis B vaccination, safe blood and injections, diagnosis and treatment of hepatitis B and C, harmful-alcohol reduction, metabolic risk care and surveillance of eligible high-risk people can reduce late presentations. Individual counselling should explain that risk persists after viral suppression or cure when advanced fibrosis or cirrhosis is present. Local surveillance capacity, imaging quality and transplant access strongly affect outcomes and must be documented rather than assumed.
Risk Factors
Cirrhosis from any cause is the central risk state. Important aetiologies include chronic hepatitis B, chronic hepatitis C, alcohol-related liver disease, metabolic dysfunction-associated steatotic liver disease, haemochromatosis and less common inherited or autoimmune disorders. Chronic hepatitis B can lead to HCC without established cirrhosis, so surveillance decisions incorporate viral, demographic, family and fibrosis factors rather than waiting for decompensation. Hepatitis C cure reduces but does not eliminate risk after advanced fibrosis or cirrhosis. Co-infection, ongoing alcohol exposure, tobacco, obesity and diabetes can compound risk.
Aflatoxin exposure has biological and public-health relevance in some settings, but it is not a clinical explanation to assign without exposure evidence. Family history, male sex and increasing age modify risk. Once cirrhosis exists, thrombocytopenia, portal hypertension and declining function influence both prognosis and treatment safety. Do not treat a normal aminotransferase or absent symptoms as evidence that risk has disappeared; HCC often remains silent until advanced.
Prevention includes universal hepatitis B immunisation under national policy, timely birth-dose delivery, safe injection and blood practices, diagnosis and evidence-based antiviral treatment, alcohol cessation support and management of obesity, diabetes and metabolic disease. Antiviral therapy is prescribed for the infection according to current criteria, not solely as an anticancer drug. Coffee, statins, aspirin or metformin should not be promoted as substitute chemoprevention. For eligible high-risk patients, EASL recommends liver ultrasound every six months; AFP may be added when the expected sensitivity gain justifies false positives and downstream testing. Poor visualisation from obesity or a nodular liver requires specialist selection of an alternative strategy rather than silent abandonment. In India, connect patients to available NVHCP-linked hepatitis care, but verify the local service. Surveillance is a repeated risk-based programme, not a one-off generic cancer-screening invitation.
Diagnosis
History
Ask about chronic hepatitis testing and treatment, vaccination, transfusion or injection exposure, alcohol amount and pattern, metabolic disease, obesity, medicines, traditional remedies and family liver cancer. Clarify weight loss, anorexia, right-upper-quadrant pain, early satiety, fever, jaundice, pruritus, abdominal distension, oedema, gastrointestinal bleeding, sleep reversal or confusion. Retrieve surveillance scans, AFP trends and prior liver imaging. Document performance status, frailty, transplant barriers and previous decompensation.
Examination
Assess airway, circulation and mental state before cancer staging. Look for wasting, jaundice, pallor, bruising, oedema, spider naevi and asterixis. Examine for hepatomegaly, a hard or nodular liver, tenderness, ascites, splenomegaly, abdominal-wall collaterals and masses. Record encephalopathy, infection, active bleeding and volume status. A palpable liver is neither necessary nor specific for HCC, and a stable examination does not exclude a surveillance-detected tumour.
Investigations
Obtain blood count, bilirubin, albumin, INR, renal function, electrolytes, transaminases, alkaline phosphatase and viral markers needed to define liver disease. AFP may assist but is not diagnostic. Characterise a lesion with properly timed multiphasic contrast CT or MRI interpreted by experienced radiology using a validated system. Non-invasive imaging diagnosis applies only in recognised at-risk groups and requires the characteristic enhancement pattern. Indeterminate lesions need interval expert imaging, an alternative modality or biopsy according to probability and consequence. Stage chest and extrahepatic disease as indicated. Biopsy requires a plan for bleeding risk, tract considerations and pathology review; obtain tissue when imaging criteria do not validly establish HCC or another tumour is plausible.
Differential Diagnosis
A liver lesion in cirrhosis may be regenerative, dysplastic or malignant. Arterioportal shunts and perfusion abnormalities can mimic arterial enhancement. Small nodules can remain indeterminate on one examination; forcing them into a cancer label creates avoidable treatment, while indefinite casual follow-up risks delay. Benign possibilities include haemangioma, focal nodular hyperplasia, hepatic adenoma, focal fat and cyst. Infections such as pyogenic or amoebic abscess enter the differential when fever, pain, inflammatory markers or epidemiology fit, but fever can also occur with necrotic tumour.
Intrahepatic cholangiocarcinoma and combined HCC-cholangiocarcinoma are critical malignant alternatives because treatment and transplant implications differ. The “targetoid” imaging pattern, capsular retraction or discordant tumour markers may raise concern but pathology is often required. Metastases are more common than primary liver cancer in many non-cirrhotic settings; search for a plausible primary rather than assuming HCC from any enhancing mass. Vascular tumours and rare primary hepatic malignancies require specialist radiology and pathology.
AFP can be normal in HCC and raised in germ-cell tumours, pregnancy, active hepatitis or hepatic regeneration. Cholangiocarcinoma may raise CA19-9 and some HCCs do not, so markers are supporting evidence rather than histology substitutes. Portal-vein thrombosis may be bland or tumour thrombus; enhancement and continuity matter. A sudden painful decline can represent tumour rupture, portal-vein thrombosis, infection or ordinary decompensation. Resolve discordance through multidisciplinary image review, repeat high-quality imaging and tissue when indicated, not by empirical chemotherapy or an unqualified ultrasound label.
Management
Stage both cancer and liver disease before choosing treatment. Multidisciplinary review integrates lesion number and size, location, macrovascular invasion, extrahepatic spread, Child-Pugh components, portal hypertension, performance status, comorbidity and transplant feasibility. The Barcelona Clinic Liver Cancer framework is useful but does not replace anatomical and patient-specific judgement. In an appropriate non-cirrhotic liver, or selected compensated cirrhosis without clinically significant portal hypertension and with an adequate future liver remnant, resection may be curative. Thermal ablation is a curative-intent option for selected small tumours when location and expertise permit.
Liver transplantation treats both tumour and cirrhotic liver in candidates meeting accepted oncological and transplant criteria. Refer early because evaluation, living- or deceased-donor pathways and bridging therapy take time. Selected patients may be downstaged within a protocol. For liver-confined disease unsuitable for immediate curative treatment, transarterial chemoembolisation, transarterial radioembolisation, stereotactic radiotherapy or other local therapy may be considered according to stage, vascular anatomy and liver reserve. Repeated locoregional treatment should stop when benefit is unlikely or liver function is being harmed.
Advanced disease may receive evidence-based systemic combination therapy or another first-line option selected by bleeding risk, autoimmune history, transplant status, organ function, performance and availability. Sequence after progression depends on previous exposure and liver function. Treat viral hepatitis and cirrhosis complications in parallel. Nutrition, pain, ascites, encephalopathy, variceal prevention, psychological support and early palliative care are active components of oncology, not evidence that disease-directed treatment has ceased.
Prescribing Information
Systemic HCC therapy must be ordered through a current oncology protocol. Immune-checkpoint and anti-angiogenic combinations can improve outcomes in selected advanced disease, but require assessment for varices and bleeding, blood pressure, proteinuria, liver function, thrombosis, wound healing, autoimmune disease, transplantation and infection. Immune-mediated hepatitis, colitis, pneumonitis, endocrinopathy and skin toxicity may appear after treatment and need prompt graded management; patients should not self-start corticosteroids or ignore jaundice. Tyrosine-kinase inhibitors have different hand-foot, gastrointestinal, hypertensive, cardiac, hepatic and interaction profiles. Exact selection, dose and modification must follow the current Indian label and formulary.
Before transarterial therapy, verify arterial anatomy, portal flow, renal function, bilirubin and liver reserve. Post-embolisation fever and pain are common, but sepsis, liver failure, biliary injury and tumour rupture must be recognised. Avoid non-steroidal anti-inflammatory drugs, sedatives or herbal products reflexively in decompensated cirrhosis. Ascites diuretics, lactulose or rifaximin, non-selective beta-blockers, antibiotics and albumin each have indication-specific dosing and monitoring; they are not generic add-ons to a cancer plan.
Continue or initiate antiviral treatment for hepatitis B or C under current infection guidance, including prophylaxis when immunosuppression may reactivate HBV. Drug interactions and renal function matter. The AASLD 2025 critical update removed support for routine adjuvant atezolizumab-bevacizumab after resection or ablation based on updated trial results; do not copy an earlier positive headline into practice. Provide written toxicity contacts, reconcile all traditional medicines and never stop anticancer, antiviral or corticosteroid therapy without the responsible team.
When to Refer
Refer any suspected HCC promptly to a hepatobiliary multidisciplinary service with hepatology or gastroenterology, liver radiology, hepatobiliary surgery, interventional radiology, medical and radiation oncology, pathology and transplant input as available. The referral should carry multiphasic images rather than only a report, lesion size and segment, vascular invasion, extrahepatic staging, AFP, blood count, bilirubin, albumin, INR, creatinine, sodium, viral status, prior decompensation, performance status and current medicines. A single-phase CT or screening ultrasound is not adequate treatment planning.
Send potentially curable disease early for resection, ablation and transplant assessment in parallel where appropriate. Transplant referral should not wait until liver function is too poor for evaluation. Seek specialist biopsy planning for lesions outside validated non-invasive criteria, indeterminate or targetoid imaging, or suspected cholangiocarcinoma. Refer to viral-hepatitis services for HBV or HCV management and screen household or other contacts according to infection guidance. Integrate dietetics, diabetes, alcohol-care, pain and palliative services based on need.
Emergency referral is required for haemodynamic instability, suspected rupture, haematemesis or melaena, acute encephalopathy, fever with ascites, severe jaundice, acute kidney injury, hypoglycaemia, sepsis or respiratory compromise from tense ascites. In India, identify whether the destination can perform liver-protocol imaging, embolisation, complex surgery or transplantation. Transfer should not be a vague instruction to “visit a cancer hospital”; confirm urgency, transport, records, financial counselling and a responsible clinician. Local teams should continue cirrhosis and symptom care while tertiary decisions are pending.
Red Flags
Sudden severe right-upper-quadrant pain, abdominal distension, shoulder-tip pain, pallor, syncope or shock may indicate HCC rupture and haemoperitoneum. Resuscitate and obtain emergency surgical or interventional-radiology support. Haematemesis, melaena, hypotension or falling haemoglobin in cirrhosis is an acute gastrointestinal-bleeding pathway, not a routine oncology review. New confusion, drowsiness, asterixis or personality change can represent hepatic encephalopathy but also infection, bleeding, renal failure, electrolyte disturbance, medicine toxicity or intracranial disease; assess precipitants urgently.
Fever with ascites, abdominal pain, hypotension or kidney injury raises concern for spontaneous bacterial peritonitis or sepsis and requires prompt diagnostic sampling and protocol-led treatment. Rapidly increasing jaundice, oliguria, severe hyponatraemia, hypoglycaemia or progressive ascites indicates decompensation. New focal weakness, seizure, severe headache, spinal pain, limb weakness or sphincter dysfunction suggests metastatic or vascular neurological emergency. Portal-vein tumour invasion can worsen portal hypertension and pain.
During systemic therapy, fever, chest pain, severe breathlessness, new bleeding, very high blood pressure, neurological change, severe diarrhoea, dehydration or deepening jaundice requires immediate toxicity assessment. After ablation or embolisation, persistent fever, peritonism, haemodynamic change, worsening encephalopathy or marked jaundice is not safely labelled routine post-procedure syndrome. Any plan should give patients and families a reachable emergency number, because delay can convert a treatable complication into organ failure. Red flags establish urgency; definitive attribution still requires clinical, laboratory and imaging assessment.
Indian Clinical Context
The National Viral Hepatitis Control Programme creates a public-health framework for hepatitis B and C prevention, testing, treatment and referral, all relevant to HCC prevention. Its operational document dates from the programme’s early rollout and reports older burden estimates; it is not a current HCC treatment guideline and does not prove that every district provides the same testing, antiviral stock or specialist follow-up. Verify local NVHCP function and connect eligible patients without promising uniform access. Hepatitis vaccination, safe blood and injection practice, antiviral care and surveillance remain major system-level opportunities.
EASL 2025 provides a contemporary international evidence framework, but European transplant allocation, medicine approvals, surveillance capacity and reimbursement cannot be assumed in India. Ultrasound quality, multiphasic CT or MRI, interventional radiology, radiotherapy, pathology, systemic medicines and liver transplantation vary sharply between regions and public, charitable and private sectors. If an optimal modality is unavailable, document the limitation and seek an evidence-based alternative or transfer; do not mislabel single-phase imaging as equivalent.
Financial toxicity is clinically relevant. Repeated travel, scans, endoscopy, locoregional procedures, immunotherapy and transplantation can exceed family resources. Discuss expected benefit, uncertainty, frequency, complications and lower-cost evidence-based options without coercion. Preserve copies of images, procedure notes, pathology, stage, liver scores, viral treatment and toxicities when care crosses centres. Living-donor discussions require independent donor safeguards. Public education must avoid stigma around alcohol or hepatitis and must not advertise AFP or ultrasound as a one-off universal cancer test. Institutional tumour-board decisions and current Indian regulatory rules govern treatment.
NMC Competency Mapping
NMC CBME Curriculum 2024 gives a direct pathology competency in PA24.7: learners should define and describe the aetiology, types, pathogenesis, morphology and complications of hepatocellular carcinoma. PA24.9 adds supervised identification of microscopic features of liver diseases and tumours. General Medicine GM5.5 integrates HCC as a complication of cirrhosis and portal hypertension, while GM5.15 requires discussion of management of hepatitis, cirrhosis, portal-hypertension complications and HCC. GM5.8 to GM5.13 cover liver history, examination, differential diagnosis and interpretation of blood and imaging investigations; GM5.17 addresses indications for hepatic transplantation.
A graduating learner should identify HBV, HCV, alcohol and metabolic disease risks; recognise silent surveillance-detected disease and decompensated presentation; and interpret the purpose and limits of AFP, ultrasound and multiphasic imaging. The learner should explain that a characteristic enhancement pattern is valid only in defined at-risk populations and that biopsy is needed when criteria are not met or another tumour is plausible. They should connect tumour stage with liver reserve and performance status.
Competency does not authorize independent biopsy, ablation, embolisation, transplant selection or systemic prescribing. Learners should recognise variceal bleeding, encephalopathy, infection, rupture and acute kidney injury as priorities before elective cancer staging. An assessed case can require formulation of a safe referral, prevention plan and explanation of resection, ablation and transplantation principles. Communication should be non-stigmatising, include prognosis uncertainty and respect financial and regional constraints without presenting unavailable care as delivered.
Key Exam Pearls for NEET PG
HCC commonly arises in cirrhosis, but chronic hepatitis B can produce HCC without cirrhosis. Major associations are HBV, HCV, alcohol-related liver disease, metabolic steatotic liver disease and aflatoxin exposure. Gross patterns include unifocal, multifocal and diffusely infiltrative tumours. Histology may show trabecular, pseudoglandular or solid growth, bile production and arterialisation. Tumour invasion of portal or hepatic veins is a major adverse feature. AFP can support surveillance and prognosis but normal AFP does not exclude HCC and a raised result is not diagnostic by itself.
In an at-risk liver, the classic imaging concept is arterial-phase hyperenhancement followed by washout on portal venous or delayed phases, interpreted within a validated system. Do not apply this shortcut to every incidental lesion in a non-cirrhotic patient. Targetoid imaging raises concern for non-HCC malignancy such as intrahepatic cholangiocarcinoma. Biopsy is considered for non-diagnostic imaging or when histology will change treatment. Stage both tumour and cirrhosis; Child-Pugh components, portal hypertension and performance status affect eligibility.
Curative-intent options are resection, thermal ablation and liver transplantation. Resection needs adequate reserve and remnant; transplantation treats tumour and cirrhosis within accepted criteria. Transarterial therapy is a central option for selected liver-limited intermediate disease, while advanced disease may need systemic therapy. Always manage hepatitis and cirrhosis complications. High-yield emergencies are rupture with haemoperitoneum, variceal bleeding, spontaneous bacterial peritonitis, encephalopathy and renal dysfunction. The best answer sends early disease to a multidisciplinary liver team rather than choosing treatment from tumour diameter alone.
Frequently Asked Questions
Can hepatocellular carcinoma be diagnosed from a high alpha-fetoprotein result alone?
No. AFP can be normal in HCC and elevated in active hepatitis, pregnancy and some other tumours. Diagnosis relies on valid multiphasic imaging criteria in a defined at-risk population or on pathology when those criteria do not apply or imaging is indeterminate. AFP may still support surveillance, prognosis and follow-up.
Why does liver function change hepatocellular-carcinoma treatment choices?
Most HCC develops in chronically diseased liver. Resection, embolisation and systemic treatment can precipitate liver failure when functional reserve or portal hypertension is poor. Decisions therefore combine tumour extent with bilirubin, albumin, INR, ascites, encephalopathy, portal hypertension, renal function and performance status rather than treating tumour size in isolation.
Does curing hepatitis C remove the need for liver-cancer surveillance?
Not necessarily. Viral cure substantially improves outcomes and lowers HCC risk, but patients who already have cirrhosis or advanced fibrosis may retain clinically important risk. Their surveillance plan should be continued or revised by a liver specialist using current guidance rather than stopped because the viral load becomes undetectable.
Which symptoms in a person with hepatocellular carcinoma require emergency care?
Shock or sudden severe abdominal pain, vomiting blood, black stools, new confusion, fever with ascites, rapidly worsening jaundice, reduced urine, severe breathlessness, seizure, focal weakness or major treatment toxicity needs urgent assessment. These may reflect rupture, bleeding, infection, decompensation, renal failure, metastasis or treatment complications.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic